Traws Pharma, Inc. (NASDAQ:TRAW - Get Free Report) major shareholder Orbimed Advisors Llc bought 597,729 shares of the company's stock in a transaction dated Thursday, April 16th. The stock was bought at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the acquisition, the insider directly owned 1,203,250 shares of the company's stock, valued at approximately $2,009,427.50. This represents a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Traws Pharma Price Performance
NASDAQ:TRAW opened at $1.21 on Wednesday. The business has a fifty day simple moving average of $1.66 and a two-hundred day simple moving average of $1.94. Traws Pharma, Inc. has a 1 year low of $0.97 and a 1 year high of $3.27. The company has a market capitalization of $12.29 million, a P/E ratio of 1.30 and a beta of 1.61.
Traws Pharma (NASDAQ:TRAW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 15th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.51. The company had revenue of $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. As a group, analysts anticipate that Traws Pharma, Inc. will post -2.62 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH raised Traws Pharma to a "strong-buy" rating in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.00.
Get Our Latest Stock Analysis on Traws Pharma
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP grew its holdings in shares of Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company's stock worth $41,000 after acquiring an additional 5,955 shares during the period. State Street Corp purchased a new stake in shares of Traws Pharma in the 4th quarter worth approximately $29,000. XTX Topco Ltd lifted its position in Traws Pharma by 294.2% in the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company's stock valued at $48,000 after acquiring an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in Traws Pharma in the 4th quarter valued at approximately $56,000. Finally, Geode Capital Management LLC lifted its position in Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company's stock valued at $70,000 after acquiring an additional 18,213 shares in the last quarter. Hedge funds and other institutional investors own 7.95% of the company's stock.
About Traws Pharma
(
Get Free Report)
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
